Using Heart Rate as a Biomarker in Clinical Practice.

Slides:

Advertisements

Similar presentations

patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.

Advertisements

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

analysis from the SHIFT study

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Ivabradine – A new option for Heart Failure Patients

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Current State of Hyperkalemia Management

Current Dyslipidemia Management Guidelines Residual Risk.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Acute Heart Failure.

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

Applying New Data in Practice:

A New Era for NOACs:.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Metastatic Renal Cell Carcinoma

Select Topics in Cardiovascular Medicine

PCP Perspectives Clinical Considerations in Hyperkalemia

Update on NSAID Use:.

Cost Effectiveness and Optimal Outcomes in HF

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Is RA Treatment Addressing the Real Needs of Patients?

Antithrombotic Protection in CAD and HF

Expert Insights on Complex Clinical Cases of Edema

Oral Anticoagulation in AF

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

Multidisciplinary Management of Hyperkalemia:

Hyperkalemia in the Hospital

Overcoming Clinical Inertia

Case #1 Case #1 (cont) Case #1 (cont)

Updates in Heart Failure:

Revisiting the Pharmacoeconomics of HF

Aspirin and Cardioprevention in 2018

Clinicians' Corner in Dyslipidemia

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

Identifying High-Risk AF Patients

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

CAD and HF Often Coexist

Typical Patient Presentation

Impedence-guided management

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Factor Xa Inhibitors in Coronary Artery Disease

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Individualizing Therapy for RA: Are We There Yet?

Real-World Evidence.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

My PAH Patient.

Top Tips in Evidence-Based Care for HFrEF

Key Data on Improving Outcomes in HF Patients

The Power of As-Treated Analyses

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Using Heart Rate as a Biomarker in Clinical Practice

New Trends in Telehealth Technology

SHIFT Trial Systolic HF Treatment With the If Inhibitor Ivabradine

Effect of Ivabradine on Outcomes

Tachycardia Is 60 the New 80?

Interpreting Data Into Practice

SHIFT and 30-Day Rehospitalization

SIGNIFY Trial Study Design

SHIFT vs SIGNIFY

SIGNIFY Conclusion Patients With Chronic Stable CAD Without HF

International Status of Heart Rate Reduction With Ivabradine

Reexamining Existing Data

Ivabradine Higher Dosing Data Still Needed

Characteristics of Ivabradine

Take Home Messages

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)